Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Valdecoxib is a COX-2 inhibitor used to treat osteoarthritis and dysmenorrhoea. Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
- Mechanism
- Curator reviewed
Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.
- Primary indication
- For the treatment of osteoarthritis and dysmenorrhoeaCurator reviewed · 3 structured indications
- Formula / weight
- C16H14N2O3S · 314.359 g/mol (avg)
- First approval
- United States, 2001
- Brand names
- Bextra
Resolves to
LNPDTQAFDNKSHK-UHFFFAOYSA-NSMILESCC1=C(C(=NO1)C1=CC=CC=C1)C1=CC=C(C=C1)S(N)(=O)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Valdecoxib, and which of those have an active Phase 3 trial?